IL156069A0 - Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma - Google Patents

Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma

Info

Publication number
IL156069A0
IL156069A0 IL15606901A IL15606901A IL156069A0 IL 156069 A0 IL156069 A0 IL 156069A0 IL 15606901 A IL15606901 A IL 15606901A IL 15606901 A IL15606901 A IL 15606901A IL 156069 A0 IL156069 A0 IL 156069A0
Authority
IL
Israel
Prior art keywords
sarp
scleroderma
endogenous
binds
receptor
Prior art date
Application number
IL15606901A
Other languages
English (en)
Original Assignee
Applied Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Res filed Critical Applied Res
Publication of IL156069A0 publication Critical patent/IL156069A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
IL15606901A 2000-12-06 2001-11-30 Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma IL156069A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (fr) 2000-12-06 2001-11-30 Utilisation de sarp-1 dans le traitement et/ou la prevention de la sclerodermie

Publications (1)

Publication Number Publication Date
IL156069A0 true IL156069A0 (en) 2003-12-23

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15606901A IL156069A0 (en) 2000-12-06 2001-11-30 Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma

Country Status (30)

Country Link
US (2) US7341995B2 (fr)
EP (2) EP1806144A3 (fr)
JP (1) JP2004525869A (fr)
KR (1) KR100804885B1 (fr)
CN (1) CN1323716C (fr)
AT (1) ATE359808T1 (fr)
AU (2) AU2002226366B2 (fr)
BG (1) BG107941A (fr)
BR (1) BR0115983A (fr)
CA (1) CA2428092A1 (fr)
CY (1) CY1107687T1 (fr)
CZ (1) CZ20031855A3 (fr)
DE (1) DE60128009T2 (fr)
DK (1) DK1411970T3 (fr)
EA (1) EA005973B1 (fr)
EE (1) EE200300213A (fr)
ES (1) ES2281463T3 (fr)
HK (1) HK1068106A1 (fr)
HR (1) HRP20030426A2 (fr)
HU (1) HUP0302738A3 (fr)
IL (1) IL156069A0 (fr)
MX (1) MXPA03005027A (fr)
NO (1) NO20032597L (fr)
NZ (1) NZ525774A (fr)
PL (1) PL365316A1 (fr)
PT (1) PT1411970E (fr)
SK (1) SK8472003A3 (fr)
UA (1) UA83790C2 (fr)
WO (1) WO2002046225A2 (fr)
YU (1) YU45103A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511010A (ja) * 1997-02-06 2001-08-07 ジェネティックス・インスチチュート・インコーポレーテッド ヒトｓｄｆ−５蛋白および組成物
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
KR20040107492A (ko) 2002-04-10 2004-12-20 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
PL3520815T3 (pl) * 2005-02-08 2022-04-11 Genzyme Corporation Przeciwciała przeciwko TGFBETA
EP1948210A4 (fr) * 2005-11-08 2010-07-14 Found Biomedical Res & Innov Methode de traitement d'une maladie cardiaque ischemique
CA2707735A1 (fr) * 2007-12-13 2009-06-18 Gabriela Saborio Proteines de fusion sarp-1 et leurs utilisations
BR112013023277A2 (pt) * 2011-03-11 2017-06-27 Celgene Corp métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0932678B2 (fr) * 1996-09-24 2010-03-10 Genentech, Inc. Famille de genes codant les peptides lies a l'apoptose, peptides ainsi codes et leurs procedes d'utilisation
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
JP2001511010A (ja) * 1997-02-06 2001-08-07 ジェネティックス・インスチチュート・インコーポレーテッド ヒトｓｄｆ−５蛋白および組成物
CN100480266C (zh) * 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途

Also Published As

Publication number Publication date
KR20030076585A (ko) 2003-09-26
DE60128009T2 (de) 2007-08-23
AU2002226366B2 (en) 2007-03-22
WO2002046225A3 (fr) 2004-01-08
ATE359808T1 (de) 2007-05-15
BG107941A (bg) 2004-01-30
EP1806144A3 (fr) 2008-04-23
DE60128009D1 (de) 2007-05-31
EP1411970A2 (fr) 2004-04-28
EA200300639A1 (ru) 2003-12-25
CY1107687T1 (el) 2012-05-23
YU45103A (sh) 2006-08-17
DK1411970T3 (da) 2007-06-04
HRP20030426A2 (en) 2005-04-30
NO20032597D0 (no) 2003-06-06
NZ525774A (en) 2006-03-31
SK8472003A3 (en) 2003-10-07
KR100804885B1 (ko) 2008-02-20
JP2004525869A (ja) 2004-08-26
CZ20031855A3 (cs) 2003-09-17
BR0115983A (pt) 2003-12-30
AU2636602A (en) 2002-06-18
US7655628B2 (en) 2010-02-02
HUP0302738A3 (en) 2010-01-28
HK1068106A1 (en) 2005-04-22
WO2002046225A2 (fr) 2002-06-13
HUP0302738A2 (hu) 2003-11-28
US7341995B2 (en) 2008-03-11
CN1553806A (zh) 2004-12-08
NO20032597L (no) 2003-06-06
ES2281463T3 (es) 2007-10-01
PT1411970E (pt) 2007-05-31
EE200300213A (et) 2003-08-15
US20080107627A1 (en) 2008-05-08
EP1806144A2 (fr) 2007-07-11
EA005973B1 (ru) 2005-08-25
EP1411970B1 (fr) 2007-04-18
CA2428092A1 (fr) 2002-06-13
PL365316A1 (en) 2004-12-27
CN1323716C (zh) 2007-07-04
US20050113291A1 (en) 2005-05-26
MXPA03005027A (es) 2003-09-05
UA83790C2 (ru) 2008-08-26

Similar Documents

Publication Publication Date Title
WO2003074551A8 (fr) Conjugues d'agents therapeutiques ou cytotoxiques et de peptides bioactifs
IL196301A0 (en) Medicament for the treatment of hapatitis c
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
HK1076387A1 (en) Use in the preparation of a combination medicament for the treatment or prevention of an immunoinflammatory disorder
MXPA02000282A (es) Composiciones de cuidado personal.
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
WO2001039777A8 (fr) Composes specifiques aux recepteurs a1, a2a et a3 de l'adenosine et leurs utilisations
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
MXPA03007903A (es) Sistema terapeutico transdermico altamente flexible con nicotina como ingrediente activo.
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
WO1999051256A3 (fr) Utilisation de l-glu-l-trp pour le traitement d'une infection par vih
HK1032534A1 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
WO2002032445A3 (fr) Proteines oxydees, leur effet biologique et mesures therapeutiques et diagnostiques decoulant du mecanisme d'action, de l'utilisation de ces proteines ou de leur inhibition
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
WO2002101394A3 (fr) Procede de criblage a l'aide des proteines bnpi et dnpi
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
ITRM20000107A0 (it) Composizione per la prevenzione e/o il trattamento degli effetti citotossici indotti dall'uso di agenti immunosoppressori.
WO2003072047A3 (fr) Compositions d'iodothyronine
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie
IT1302508B1 (it) Dispositivo per applicazioni terapeutiche al corpo umano.
ZA981275B (en) Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions.